Clinical Trial Update: Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and effectiveness of the oral CCR5 antagonist INCB009471 in patients with R5-tropic HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• INCB009471

Snippet

Sponsor: Incyte Corporation | Conditions: HIV Infections | Phase 2 | Status: COMPLETED